FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3163996556> ?p ?o ?g. }

• W3163996556 abstract "The combination of BRAF and MEK inhibitors has become standard of care in the treatment of metastatic BRAF V600-mutated melanoma. Clinical factors for an early prediction of tumor response are rare. The present study investigated the association between the development of an early exanthema induced by vemurafenib or vemurafenib plus cobimetinib and therapy outcome.This multicenter retrospective study included patients with BRAF V600-mutated irresectable AJCC-v8 stage IIIC/D to IV metastatic melanoma who received treatment with vemurafenib (VEM) or vemurafenib plus cobimetinib (COBIVEM). The development of an early exanthema within six weeks after therapy start and its grading according to CTCAEv4.0 criteria was correlated to therapy outcome in terms of best overall response, progression-free (PFS), and overall survival (OS).A total of 422 patients from 16 centers were included (VEM, n=299; COBIVEM, n=123). 20.4% of VEM and 43.1% of COBIVEM patients developed an early exanthema. In the VEM cohort, objective responders (CR/PR) more frequently presented with an early exanthema than non-responders (SD/PD); 59.0% versus 38.7%; p=0.0027. However, median PFS and OS did not differ between VEM patients with or without an early exanthema (PFS, 6.9 versus 6.0 months, p=0.65; OS, 11.0 versus 12.4 months, p=0.69). In the COBIVEM cohort, 66.0% of objective responders had an early exanthema compared to 54.3% of non-responders (p=0.031). Median survival times were significantly longer for patients who developed an early exanthema compared to patients who did not (PFS, 9.7 versus 5.6 months, p=0.013; OS, not reached versus 11.6 months, p=0.0061). COBIVEM patients with a mild early exanthema (CTCAEv4.0 grade 1-2) had a superior survival outcome as compared to COBIVEM patients with a severe (CTCAEv4.0 grade 3-4) or non early exanthema, respectively (p=0.047). This might be caused by the fact that 23.6% of patients with severe exanthema underwent a dose reduction or discontinuation of COBIVEM compared to only 8.9% of patients with mild exanthema.The development of an early exanthema within 6 weeks after treatment start indicates a favorable therapy outcome upon vemurafenib plus cobimetinib. Patients presenting with an early exanthema should therefore be treated with adequate supportive measures to provide that patients can stay on treatment." @default.
• W3163996556 created "2021-06-07" @default.
• W3163996556 creator A5007887862 @default.
• W3163996556 creator A5013474977 @default.
• W3163996556 creator A5015081105 @default.
• W3163996556 creator A5017486762 @default.
• W3163996556 creator A5018661840 @default.
• W3163996556 creator A5021812411 @default.
• W3163996556 creator A5024012524 @default.
• W3163996556 creator A5031315234 @default.
• W3163996556 creator A5034365278 @default.
• W3163996556 creator A5040320971 @default.
• W3163996556 creator A5040652983 @default.
• W3163996556 creator A5044487752 @default.
• W3163996556 creator A5057381405 @default.
• W3163996556 creator A5064923908 @default.
• W3163996556 creator A5067776208 @default.
• W3163996556 creator A5072203765 @default.
• W3163996556 creator A5076387862 @default.
• W3163996556 creator A5077331259 @default.
• W3163996556 creator A5080522810 @default.
• W3163996556 creator A5084108111 @default.
• W3163996556 creator A5090872399 @default.
• W3163996556 date "2021-05-24" @default.
• W3163996556 modified "2023-10-18" @default.
• W3163996556 title "Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study" @default.
• W3163996556 cites W1974386387 @default.
• W3163996556 cites W2128542677 @default.
• W3163996556 cites W2139248078 @default.
• W3163996556 cites W2338010368 @default.
• W3163996556 cites W2491982852 @default.
• W3163996556 cites W2605630889 @default.
• W3163996556 cites W2762347490 @default.
• W3163996556 cites W2765615653 @default.
• W3163996556 cites W2885790309 @default.
• W3163996556 cites W2888349826 @default.
• W3163996556 cites W2896600825 @default.
• W3163996556 cites W2897059317 @default.
• W3163996556 cites W2912365614 @default.
• W3163996556 cites W2913619761 @default.
• W3163996556 cites W2935291092 @default.
• W3163996556 cites W2946687934 @default.
• W3163996556 cites W2948361993 @default.
• W3163996556 cites W3010238254 @default.
• W3163996556 doi "https://doi.org/10.3389/fonc.2021.672172" @default.
• W3163996556 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8183381" @default.
• W3163996556 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34109122" @default.
• W3163996556 hasPublicationYear "2021" @default.
• W3163996556 type Work @default.
• W3163996556 sameAs 3163996556 @default.
• W3163996556 citedByCount "2" @default.
• W3163996556 countsByYear W31639965562022 @default.
• W3163996556 countsByYear W31639965562023 @default.
• W3163996556 crossrefType "journal-article" @default.
• W3163996556 hasAuthorship W3163996556A5007887862 @default.
• W3163996556 hasAuthorship W3163996556A5013474977 @default.
• W3163996556 hasAuthorship W3163996556A5015081105 @default.
• W3163996556 hasAuthorship W3163996556A5017486762 @default.
• W3163996556 hasAuthorship W3163996556A5018661840 @default.
• W3163996556 hasAuthorship W3163996556A5021812411 @default.
• W3163996556 hasAuthorship W3163996556A5024012524 @default.
• W3163996556 hasAuthorship W3163996556A5031315234 @default.
• W3163996556 hasAuthorship W3163996556A5034365278 @default.
• W3163996556 hasAuthorship W3163996556A5040320971 @default.
• W3163996556 hasAuthorship W3163996556A5040652983 @default.
• W3163996556 hasAuthorship W3163996556A5044487752 @default.
• W3163996556 hasAuthorship W3163996556A5057381405 @default.
• W3163996556 hasAuthorship W3163996556A5064923908 @default.
• W3163996556 hasAuthorship W3163996556A5067776208 @default.
• W3163996556 hasAuthorship W3163996556A5072203765 @default.
• W3163996556 hasAuthorship W3163996556A5076387862 @default.
• W3163996556 hasAuthorship W3163996556A5077331259 @default.
• W3163996556 hasAuthorship W3163996556A5080522810 @default.
• W3163996556 hasAuthorship W3163996556A5084108111 @default.
• W3163996556 hasAuthorship W3163996556A5090872399 @default.
• W3163996556 hasBestOaLocation W31639965561 @default.
• W3163996556 hasConcept C121608353 @default.
• W3163996556 hasConcept C126322002 @default.
• W3163996556 hasConcept C143998085 @default.
• W3163996556 hasConcept C167135981 @default.
• W3163996556 hasConcept C2776131300 @default.
• W3163996556 hasConcept C2777658100 @default.
• W3163996556 hasConcept C2780739268 @default.
• W3163996556 hasConcept C2994587330 @default.
• W3163996556 hasConcept C3019894029 @default.
• W3163996556 hasConcept C502942594 @default.
• W3163996556 hasConcept C71924100 @default.
• W3163996556 hasConcept C72563966 @default.
• W3163996556 hasConceptScore W3163996556C121608353 @default.
• W3163996556 hasConceptScore W3163996556C126322002 @default.
• W3163996556 hasConceptScore W3163996556C143998085 @default.
• W3163996556 hasConceptScore W3163996556C167135981 @default.
• W3163996556 hasConceptScore W3163996556C2776131300 @default.
• W3163996556 hasConceptScore W3163996556C2777658100 @default.
• W3163996556 hasConceptScore W3163996556C2780739268 @default.
• W3163996556 hasConceptScore W3163996556C2994587330 @default.
• W3163996556 hasConceptScore W3163996556C3019894029 @default.
• W3163996556 hasConceptScore W3163996556C502942594 @default.
• W3163996556 hasConceptScore W3163996556C71924100 @default.
• W3163996556 hasConceptScore W3163996556C72563966 @default.

• next